

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently Amended) A method of ~~vaccinating~~ modulating an immune response in a mammal to a selected antigen, the method comprising

administering to a mammal a ~~vaccine~~ composition comprising a cytokine-coated cell comprising said selected antigen, wherein said cytokine of said cytokine-coated cell is exogenous to said cell, and wherein ~~said mammal is vaccinated~~ an immune response is modulated in said mammal to said selected antigen.

2. (Currently Amended) A method of ~~vaccinating~~ modulating an immune response in a mammal to a selected antigen, the method comprising

administering to a mammal a ~~vaccine~~ composition comprising a cytokine-coated cell, wherein said cytokine of said cytokine-coated cell is exogenous to said cell, wherein said cytokine-coated cell comprises said selected antigen and is admixed with an engineered cytokine, and wherein ~~said mammal is vaccinated~~ an immune response is modulated in said mammal to said selected antigen.

3. (Currently Amended) The method of claim 1 or claim 2 wherein said ~~vaccine~~ composition further comprises an opsonin-enhanced cell.

4. (Original) The method of claim 3 wherein said opsonin of said opsonin-enhanced cell is selected from the group consisting of mannose binding protein or the alpha' chain of C3b.

5. (Original) The method of any one of claims 1 or 2 wherein said cytokine of said cytokine-coated cell comprises a lipid.

6. (Original) The method of claim 5 wherein said cytokine comprises a GPI moiety.

7. (Original) The method of claim 5 wherein said cytokine comprises a fatty acid.

8. (Original) The method of claim 7 wherein said fatty acid is palmitate.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Currently Amended) A method of ~~vaccinating~~ modulating an immune response in a mammal to a selected antigen, the method comprising administering to the mammal a ~~vaccine~~ composition comprising a cytokine-coated cell, wherein said cytokine of said cytokine-coated cell is exogenous to said cell, wherein said cytokine is a ligand for the GM-CSF receptor, and wherein ~~said mammal is vaccinated~~ an immune response is modulated in said mammal to said selected antigen.

14. (Original) The method of claim 13, wherein said ligand for the GM-CSF receptor is GM-CSF.

15. (Cancelled) A method of ~~vaccinating~~ modulating an immune response in a mammal to a selected antigen, the method comprising; administering to a mammal a ~~vaccine~~ composition comprising a cytokine-coated cell, wherein said cytokine of said cytokine-coated cell is exogenous to said cell, wherein said cytokine is a ligand for one of the following receptors: the IL-2 receptor, the IL-4 receptor, the IL-6 receptor, the IL-10 receptor, the IL-12 receptor, the TNF- $\alpha$  receptor, the IFN- $\gamma$  receptor, a chemokine receptor.

16. (Cancelled) The method of claim 15, wherein said ligand is selected from the group consisting of: IL-2, IL-4, IL-6, IL-10, IL-12, TNF- $\alpha$ , IFN- $\gamma$ , or a chemokine.

17. (Previously Amended) The method of any one of claims 1 or 13, wherein said cell of said cytokine-coated cell is a pathogenic cell.

18. (Original) The method of claim 17 wherein said pathogenic cell is a malignant tumor cell.

19. (Currently Amended) The method of claim 17 wherein said cell of said pathogenic cell is selected from the group consisting of: a bacterium, a virus, a fungus, and a cell of a parasite.
20. (Original) The method of claim 17, wherein said ~~vaccine~~ composition further comprises an opsonin-enhanced pathogenic cell.
21. (Cancelled)
22. (Previously Amended) The method of any one of claims 1 or 13 wherein said cytokine-coated cell is substantially unable to divide in vitro.
23. (Currently Amended) The method of any one of claims 1 or 13, wherein said ~~vaccine composition~~ cytokine-coated cell is attenuated.
24. (Previously Amended) The method of any one of claims 1 or 13, wherein said cytokine is an antitumor cytokine.
25. (Previously Amended) The method of any one of claims 1 or 13, wherein said cytokine is extremely bioactive, natively bioactive, or suprabioactive.